Clinical efficacy and safety of atorvastatin combined with alendronate sodium in the treatment of senile osteoporosis
10.13699/j.cnki.1001-6821.2016.04.008
- VernacularTitle:阿托伐他汀联合阿仑膦酸钠治疗老年性骨质疏松的临床疗效及安全性评价
- Author:
Wei-Qi WANG
1
;
Xuan-Liang RU
;
Chun LIU
;
Zeng-Hui JIANG
Author Information
1. 浙江医院骨科
- Keywords:
atorvastatin;
alendronate sodium;
senile osteoporosis;
clinical efficacy;
safety
- From:
The Chinese Journal of Clinical Pharmacology
2016;(4):312-314
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical efficacy and safety of atorvastatin combined with alendronate sodium in the treatment of senile osteoporosis.Methods Sixty-four cases of senile osteoporosis patients were randomly divided into control group ( n =32 ) and experimental group(n=32).The control group was treated with oral alendronate sodi-um 70 mg, once a week.The experimental group was treated with alen-dronate sodium 70 mg, once a week and atorvastatin 20 mg, once a day.The course of treatment for two groups was half a year.The clinical effi-cacy, bone density, visual analogue scale (VAS) and adverse drug reac-tions were compared between the two groups.Results After treatment, total effective rate in experimental group was significantly higher than that of control group (96.88%vs 78.13%, P<0.05).After the treatment, the bone mineral density of the forearm , femoral neck , lumbar spine and femoral neck in the experimental group were significantly higher than those in the control group ( P <0.05 ).After the treatment , the VAS score of the experimental group was significantly higher than that of the control group ( P<0.05 ).The adverse drug reactions rate in the experi-mental group was 46.88%, which was significantly lower than that in the control group ( P <0.05 ).Conclusion Atorvastatin combined with alendronate sodium has a definitive clinical efficacy for the treatment of senile osteoporosis , and it can effectively improve the patients′bone density.At the same time it can relieve the pain of patients and reduce the incidence of adverse drug reactions.
